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Abstract
Background: Over the last decade there has been a paradigm shift in the management of breast
cancer, subsequent to revised surgical oncology guidelines and consensus statements which were
derived in light of landmark breast cancer clinical trials conducted throughout the latter part of the
20th century. However the sheer impact of this paradigm shift upon all modalities of treatment,
and the current trends in management of the disease, are largely unknown. We aimed to assess the
changing practices of breast cancer management over the last decade within a specialist tertiary
referral Breast Cancer Centre.
Methods: Comparative analysis of all aspects of the management of breast cancer patients, who
presented to a tertiary referral Breast Cancer Centre in 1995/1996 and 2005/2006, was
undertaken and measured against The European Society for Surgical Oncology guidelines for the
surgical management of mammographically detected lesions [1998].
Results: 613 patients' case profiles were analysed. Over the last decade we observed a dramatic
increase in incidence of breast cancer [>100%], a move to less invasive diagnostic and surgical
therapeutic techniques, as well as increased use of adjuvant therapies. We also witnessed the
introduction of immediate breast reconstruction as part of routine practice
Conclusion: We demonstrate that radical changes have occurred in the management of breast
cancer in the last decade, in keeping with international guidelines. It remains incumbent upon us to
continue to adapt our practice patterns in light of emerging knowledge and best evidence.
Background
Breast cancer is the commonest female malignancy in the
developed world, and its incidence continues to rise. The
Irish National Cancer Registry predicts that by 2020 there
will be approximately 5000 new cases per annum in Ire-
land [1]. Over the past two decades awareness of the dis-
ease has increased dramatically, and in conjunction with
increasing knowledge and understanding the manage-
ment of breast cancer has evolved. Following several land-
mark clinical trials conducted throughout the mid to latter
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part of the 20th century [Veronesi, Sarrazin, Fisher, 2-7],
the mid-1990s saw the publication of numerous sets of
guidelines advocating a less radical surgical therapeutic
approach, when combined with adjuvant radiotherapy,
encouraging increased use of systemic therapies for estro-
gen responsive tumours, emphasising the importance of
multidisciplinary team management, and highlighting a
growing awareness of the psychosocial needs of breast
cancer patients. The European Society for Surgical Oncol-
ogy put forth recommendations which included specific
targets and outcome measures, and a proposed frame-
work for surgical quality assurance in breast cancer units,
and recommended that these guidelines be reviewed and
modified in 3 years in light of new knowledge [2]. Since
the publication of these guidelines there has been a para-
digm shift in the management of breast cancer, towards
less invasive diagnostic modalities and surgical approach,
which has ameliorated both the physical and psychologi-
cal morbidity for women with this disease. The introduc-
tion of breast cancer screening has changed the type and
stage of disease at presentation, and poses specific thera-
peutic challenges. Newer more specific adjuvant therapies
and protocols have been trialled and are in widespread
clinical use. The emphasis on women's psychosocial
health following breast cancer treatment has drawn atten-
tion to the aesthetic outcome and the potential benefits of
immediate breast reconstruction. However the sheer
impact of this paradigm shift upon all modalities of treat-
ment and the current trends in management of the disease
are largely unknown. We aim to assess the changing prac-
tices of breast cancer management over the last decade
within a specialist tertiary referral Breast Cancer Centre.
Methods
A comprehensive comparative analysis was performed of
the management of breast cancer patients who presented
to a tertiary referral Breast Cancer Centre in 2005/2006,
with those who presented in 1995/1996. All patients diag-
nosed with breast cancer in our unit during these years
were identified from a prospectively collected database.
The demographic characteristics, clinical, operative and
histopathological records and follow-up details were
reviewed. We compared all new breast cancer cases from
these two 24 month periods with respect to the following
parameters: incidence, age at diagnosis, diagnostic proce-
dure, histologic type and grade, nodal status, stage [TNM]
and prognostic index, primary surgical therapeutic proce-
dure, adjuvant therapy, and subsequent surgical proce-
dures. The staging method for all patients, which was
applied retrospectively for the purpose of this review, was
the 2003 Revised TNM Staging System for Breast Cancer
[3].
All data were analysed using the software package SPSS
15.0 for Windows. Both the number of observations and
percentages are presented to describe categorical variables.
Differences in management between the groups of
patients were calculated by means of two-sample t-test for
all two sample comparisons, and the chi square test for
binomial comparisons when appropriate. All tests were
two tailed and a p-value of <0.05 was assumed to repre-
sent statistical significance.
Results
A total of 613 patients were identified for inclusion in this
study. Patients in both groups had similar demographic
characteristics, including gender, and age at diagnosis
[Table 1]. The overall incidence of breast cancer for 1995/
1996 was 202, compared with 411 cases in 2005/2006.
This represents a greater than two-fold increase over a dec-
ade.
The diagnostic modalities utilised in the diagnosis of
breast cancer has changed dramatically over the last dec-
ade. In 1995/1996, 93% [n = 188] of patients underwent
a surgical excision biopsy under general anaesthetic in
order to achieve the diagnosis. In contrast, in 2005/2006,
91% [n = 374] of our patients had a preoperative diagno-
sis established with a tru-cut or core biopsy, which was
performed under local anaesthetic in the outpatients
Table 1: Demographic details and tumour characteristics of the patients
1995/1996 2005/2006 p-value
New cases 202 411
Gender: females 99% 99% NS (t-test)
Mean age (range) 58 years (26-93) 58 years (27-93) NS (t-test)
Tumour size (mean) 28.5 mm (SD 22.6) 25.66 mm (SD 22.1) NS (t-test)
Tumour type Invasive 94% Invasive 87% NS (chi square)
DCIS 6% DCIS 13%
Invasive subtype Ductal 80% Ductal 75%
Lobular 15% Lobular 14% NS (chi square)
Other 5% Other 11%
(NS = nonsignificant)BMC Surgery 2009, 9:15 http://www.biomedcentral.com/1471-2482/9/15
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department. This refinement towards less invasive diag-
nostic modalities was statistically significant [χ2  =
0.0001].
The tumour type seen at time of diagnosis was similar in
both groups - invasive carcinoma was identified in 86% [n
= 174] of patients in 1995/1996 and in 87% [n = 358] in
2005/2006. A preoperative diagnosis of ductal carcinoma
in-situ [DCIS] was made in 13% of patients in 2005/2006
whereas in-situ carcinoma was only documented in 6% of
patients from 1995/1996. The invasive histological sub-
types are illustrated in Figure 1.
The most dramatic metamorphosis observed was in
respect to patients' primary therapeutic surgical proce-
dure. In 1995/1996, 85% [n = 172] of patients underwent
a primary mastectomy compared to only 32% [n = 131] of
patients in 2005/2006 [χ2< 0.00005]. Conversely in
1995/1996, only 15% [n = 30] underwent breast conserv-
ing surgery compared to 68% [n = 280] of patients in
2005/2006. Management of the axilla also underwent
dramatic revolution, towards a less invasive approach. In
1995/1996 the axilla was managed primarily with a for-
mal axillary clearance for all patients [n = 202] whereas in
2005/2006 61% [n = 250] of patients underwent a senti-
nel node biopsy [SNB]. More recently, a primary axillary
clearance was only performed where there was preopera-
tive radiological or histological confirmation of meta-
static disease. If the SNB was positive for macroscopic
disease, an axillary clearance was undertaken. In the 2 year
period [2005/2006] only 32% [n = 80] of the SNB popu-
lation had a positive biopsy, necessitating axillary clear-
ance.
Increasing awareness and recognition of DCIS, coupled to
patients expectations for good cosmetic outcome follow-
Invasive histological subtype at diagnosis for new breast cancer patients in 1995/1996 [n = 174] compared with 2005/2006 [n =  358] Figure 1
Invasive histological subtype at diagnosis for new breast cancer patients in 1995/1996 [n = 174] compared with 
2005/2006 [n = 358].BMC Surgery 2009, 9:15 http://www.biomedcentral.com/1471-2482/9/15
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ing oncological breast surgery, has driven the introduction
of immediate breast reconstruction in our unit. The
period 2005/2006 saw 148 reconstructive procedures per-
formed, the majority of which were latissimus dorsi flap
reconstructions [n = 95]. As breast reconstruction follow-
ing oncological surgery only came in vogue in the mid
1990's, allied to the paucity of evidence to support its rou-
tine use, no reconstructions were performed in our unit in
1995/1996.
Despite efforts to facilitate early diagnosis, our data show
no change with respect to stage of disease at presentation
over the last decade [Table 1]. Mean tumour size did not
change significantly; 28.5 mm in 1995/1996 versus 25.6
mm in 2005/2006, p = 0.133 [Figure 2]. The proportions
of T1 and T2 tumours in 1995/1996 were 28.5% and
37.5% respectively compared with 26% and 38.5% for
2005/2006 [p = 0.306]. There was a trend towards fewer
patients having node positive disease at diagnosis - 56%
in 1995/1996 versus 52% in 2005/2006 though this
decrease was not reach statistical significance [p = 0.195].
However, a greater proportion of patients were identified
as having distant metastatic disease at presentation in the
2005/2006 period; 10.5% [n = 43] compared with only
4.5% [n = 9] in 1995/1996 [p = 0.031]. This likely reflects
improvements in diagnostic radiology.
Finally, the last decade has witnessed a transformation in
our use of adjuvant treatments for breast cancer. With
recent data supporting a disease-free and overall survival
benefit associated with adjuvant chemotherapy, particu-
larly for younger patients, a greater proportion of our
patient population are having adjuvant therapy. Forty-two
[42%] percent of our patients in 2005/2006 received adju-
vant chemotherapy versus 32% in 1995/1996 [p < 0.001].
The last decade has seen the introduction of neo-adjuvant
chemotherapy in our unit for breast cancer patients and in
2005/2006 7% [n = 29] received preoperative chemother-
apy in an attempt to facilitate less radical surgical resec-
tion, or downstage the disease. Similarly, the use of local
radiotherapy has increased over the last decade, from 17%
to 74% [p < 0.0001], reflecting its recommended use in
the adjuvant setting in conjunction with minimally inva-
sive surgical resection.
Discussion
Accurate preoperative diagnosis and staging of breast can-
cer is of critical importance to facilitate a tailored surgical
approach for each individual patient. The European Soci-
ety for Surgical Oncology guidelines a decade ago recom-
mended that the majority [more than 70%] of breast
cancers should receive a pre-operative diagnosis by fine
needle cytology or core biopsy [2]. Until the mid 1990's
the gold standard diagnostic modality in breast cancer
was a surgical excision biopsy. This involved day case
admission, a general anaesthetic and a surgical scar. Since
the conception of automated core biopsy guns in the mid
1990s, needle core biopsy has been established as a highly
accurate diagnostic modality, supplanting the require-
ment for excision biopsy [4]. It is more cost effective, less
invasive and therefore less traumatic to the patient,
requires only a local anaesthetic, and can be performed
routinely in the outpatient department as part of the triple
assessment protocol [5,6]. Core biopsy is currently the
gold standard diagnostic technique utilized in our unit
and our results show that over the last decade we have
adapted best practice recommendations in achieving a
preoperative diagnosis with core biopsy for 91% of
patients.
For over 80 years, Halsted's radical mastectomy was the
surgical treatment of choice for breast cancer, irrespective
of tumour size, type or patient age [7]. The late 1970's rep-
resented the embryonic stage of breast conserving cancer
surgery, with the phenomenon of breast conserving sur-
gery providing adequate oncological resection without
compromising patient outcome or survival, being estab-
lished. Data from randomized controlled trials conducted
in the late 1970's and 1980's established equivalent effi-
cacy of breast conserving surgery, in conjunction with
radiotherapy, when compared with the traditional radical
mastectomy, for the treatment of patients with early stage
invasive breast cancer [Stage I and II] [8-11]. Henceforth,
the recommended treatment approach to early breast can-
cer was lumpectomy with a margin of normal breast tis-
Tumour size at diagnosis for breast cancer diagnosed in  1995/1996, compared with tumour size in 2005/2006 Figure 2
Tumour size at diagnosis for breast cancer diagnosed 
in 1995/1996, compared with tumour size in 2005/
2006. [T1: < 2 cm, T2: 2-5 cm, T3: > 5 cm, T4: any size with 
distant spread, I-S: in-situ carcinoma, Other: size not possible 
to determine].BMC Surgery 2009, 9:15 http://www.biomedcentral.com/1471-2482/9/15
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sue, followed by local radiotherapy. This was shown to
reduce local recurrence rates, though had no effect on long
term survival when compared to the traditional surgical
approach [12-14]. These evidence based recommenda-
tions set a new international standard for breast cancer
management [15]. This study illustrates how these recom-
mendations have influenced practice in our unit over the
last decade, leading to revolutionary changes in our
approach to management of breast cancer patients. We
have witnessed a major metamorphosis in diagnostic
modalities and primary therapeutic approaches, from tra-
ditional radical techniques to a less invasive approach
overall. In keeping with this change to breast conserving
surgery, the use of local radiotherapy in our unit has
increased significantly over the last ten years.
Historically, breast cancer treatment was associated with
significant psychosocial morbidity. Clinicians and
patients currently place greater emphasis and importance
on the cosmetic, psychological, social and emotional out-
comes following breast cancer surgery [16]. Many data
have shown that immediate breast reconstruction [IBR] is
associated with reduced psychological and sexual morbid-
ity, improved physical and emotional outcomes and over-
all improved quality of life compared to patients who
undergo mastectomy without reconstruction [17,18].
Consequently IBR following mastectomy has evolved in
our unit, in appropriately selected patients requiring mas-
tectomy as the primary therapeutic procedure, and cur-
rently 67% of women requiring a mastectomy undergo
IBR.
Adjuvant therapy for breast cancer (hormonal treatments,
radiotherapy, and systemic chemotherapy) has also
undergone dramatic transformation over the past decade.
In 2000, the Dutch National Breast Cancer Platform
[NABON] and the Dutch Society for Medical Oncology
[NVMO] published a comprehensive consensus state-
ment on adjuvant systemic therapy [19,20]. It recom-
mended tamoxifen use for patients with node-positive
tumours and a positive oestrogen receptor [ER] and/or
progesterone receptor [PR]. Chemotherapy is recom-
mended for all node-positive tumours in premenopausal
women, and in postmenopausal women under age 70
who had negative hormonal receptor status. For node-
negative tumours, the recommendation of adjuvant ther-
apy also depends on the tumour size, differentiation grade
and mitotic activity index. Prior to the introduction of the
Dutch guidelines, tamoxifen was recommended for post-
menopausal women with node-positive, ER positive
tumours while chemotherapy was reserved for premeno-
pausal women with node-positive tumours. Our data
reflects the uptake of these recommendations for appro-
priate use of systemic therapies over the last decade.
Conclusion
This study has demonstrated that radical changes have
occurred in the management of breast cancer in the last
decade. The current minimally invasive diagnostic proce-
dures and availability of sophisticated imaging techniques
facilitate the planning of accurate individual management
regimens preoperatively. Breast conserving surgery with
adjuvant radiotherapy and immediate breast reconstruc-
tion has been shown not only to be safe and effective but
also to reduce patients' associated psychosocial morbid-
ity. Similarly minimal axillary surgery has been shown to
provide the necessary prognostic information regarding
management of the axilla, obviating the need for routine
axillary clearance with its associated morbidity. Breast
cancer management has undergone a seismic revolution
in the last decade with immense benefit to the patient,
and it is encouraging to see how we have remained abreast
of new developments in breast cancer management over
that time. It remains incumbent upon us to continue to
adapt our practice patterns in light of emerging knowl-
edge. There is need for continuous reviews of breast cancer
literature, consequent revisions of management guide-
lines, and audit of practice patterns, to ensure that quality
care continues to be delivered in accordance with best
available evidence.
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